Clinical Trial

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Study acronym: COMO-1
Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-04; most recent amendment 2026-05-26.
Status change: Active, Not Recruiting → Completed 2026-05-21
Trial Details
NCT Number NCT06867718
Lead Sponsor Regor Pharmaceuticals Inc.
Conditions Obesity or Overweight
Enrollment 267 participants
Start Date 2025-01-24
Primary Completion 2025-11-06 (estimated)
Study Completion 2025-11-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-28